Log In
Print this Print this

Diquas, diquafosol (DE-089)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionSecond-generation uridine nucleotide analog P2Y receptor agonist
Molecular Target Purinergic receptor P2Y G protein-coupled 2 (P2RY2) (P2Y2)
Mechanism of ActionP2Y2 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDry eye
Indication DetailsTreat corneal and conjunctival epithelial disorder associated with dry eye
Regulatory Designation
PartnerSanten Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today